Significant pre-clinical results on the anti-tumor activity of Titanocene Y on human breast tumors and in a mouse model have just been published. In the mouse model, a decrease not only in tumor growth but also a reduction in tumor volume to around one-third was observed for the first time. In the human breast cancer, Titanocene Y showed cell death induction comparable to the widely-used chemotherapy drug Cisplatin.